IDEX Corp

NYSE:IEX

Earnings Call Analysis

IDEX Navigates Market Uncertainty with Stable Execution

IDEX Corporation reported solid performance in Q2 2024 despite macroeconomic challenges. Net income was $141 million, translating to an EPS of $1.86. Adjusted net income was $156 million, down 7%, with an adjusted EPS of $2.06. Revenue reached $807 million, a 5% decrease year-over-year. The company revised its full-year outlook, expecting a 1-2% decline in revenue. For Q3, organic sales growth is forecasted at 0-1%, with adjusted EPS between $1.85 and $1.90. IDEX focuses on operational productivity and innovation to navigate market uncertainties and drive profitability.

Strong Execution Amid Uncertainty

IDEX Corporation delivered solid results in the second quarter of 2024, despite a backdrop of increasing macroeconomic uncertainty. The company's adjusted EBITDA margin and adjusted EPS slightly exceeded previous guidance, thanks to the strong execution of teams worldwide. However, project commitments have seen a delay as clients await clearer economic and political signals.

Segment Performance Overview

IDEX's Fluid & Metering Technologies (FMT) saw a 4% organic decline in orders, largely due to cyclical downturns in the agricultural market and postponed industrial projects. Meanwhile, the Health & Science Technologies (HST) segment experienced a 5% increase in organic orders but an 11% decrease in organic sales, driven by pressures in the life sciences and analytical instrumentation markets. Fire & Safety/Diversified Products (FSDP) witnessed a 6% rise in organic orders, primarily from the North American OEM demand.

Margin Dynamics

Adjusted EBITDA margins varied across segments, reflecting disparate market conditions. Overall, the adjusted EBITDA margin decreased by 60 basis points year-over-year but improved sequentially by 180 basis points due to strong operational efficiency and favorable price costs. Productivity gains and cost reductions partially offset the impacts of lower volume leverage and higher employee-related costs.

Strategic Moves and Innovations

IDEX continues to align its business with market demands through strategic acquisitions and cutting-edge innovations. The acquisition of Mott Corporation, specializing in porous material structures and flow control solutions, is expected to drive strong organic growth and immediate EPS accretion. Moreover, the company won the Biotech Innovation Award for its MP350 Microlyser Processor, designed for large-scale cell disruption in biotech manufacturing.

Financial Highlights and Guidance

The quarter ended with IDEX having orders of $772 million, up 1% reported and 2% organically. Sales were down 5% reported and 4% organically at $807 million. The company projects a modest organic sales increase of 0-1% for Q3, with an adjusted EBITDA margin of approximately 27%. Full-year guidance has been revised, projecting a 1-2% revenue decline and adjusted EPS in the range of $7.80 to $7.90.

Focus on Operational Efficiency and Future Prospects

IDEX remains focused on stripping complexity out of its operations while driving profitability. The company has maintained a backlog profile typical for its business, assuring about half a quarter's worth of orders. There is a cautious optimism concerning the semiconductor market, where major players anticipate strong growth in 2025. The life science and analytical instrumentation markets are expected to inflect positively around the same time, positioning IDEX well for future growth.

Earnings Call Transcript 2024-Q2

[Operator]

Hello, and welcome to the IDEX Corporation Q2 2024 Earnings Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.

It's now my pleasure to turn the call over to Wendy Palacios, Vice President, Investor Relations, FP&A. Wendy, please go ahead.

[Wendy Palacios, executive]

Good morning, everyone. This is Wendy Palacios, Vice President of FP&A and Investor Relations for IDEX Corporation. Thank you for joining us for our discussion of the IDEX Second Quarter 2024 Financial Highlights.

Last night, we issued a press release outlining our company's financial and operating performance for the 3 months ending June 30, 2024. The press release, along with the presentation to be used during today's webcast, can be accessed at our investor website at investors.idexcorp.com.

Joining me today are Eric Ashleman, our Chief Executive Officer and President; and Abhi Khandelwal, our Senior Vice President and Chief Financial Officer. Following our prepared remarks, we will open the call up for your questions.

Turning to Slide 2. Please note that during today's call, we will present certain non-GAAP financial measures. We will also make forward-looking statements within the meaning of the federal securities laws, including statements regarding events or developments that we expect or anticipate will or may occur in the future.

These forward-looking statements are subject to risks and uncertainties. Actual results might differ materially from any forward-looking statements that we make today, and we do not assume any obligation to update that. Information regarding these factors may cause actual results to differ materially from these forward-looking statements is available on our website and our SEC filings.

With that, I'll now turn this call over to CEO and President, Eric Ashleman.

[Eric Ashleman, executive]

Thanks, Wendy, and good morning, everyone. I'm on Slide 3.

IDEX delivered against expectations in Q2 despite increasing macro uncertainty, with both adjusted EBITDA margin and adjusted EPS coming in slightly above our previous guidance. I'd like to thank the IDEX teams around the world for their strong execution on behalf of our customers and shareholders.

As mentioned on our first quarter call, we saw a noticeable uptick in industrial day rates in our closest to consumption FMT businesses in December. This continued through the end of February, but pulled back a bit in March as a surprisingly firm inflation report reduced the likelihood of near-term interest rate relief. These daily order rates are largely stable now and in line with our original 2024 assumptions.

However, as the U.S. election cycle has come into full daily view, creating even more uncertainty given the perceived disparity of outcomes, we've seen a pullback in project commitments. There's no talk of project cancellation, just a quarter or 2 push to the right. We'll continue to watch these businesses as open economic and political questions are resolved for any early signs of inflection.

Within the HST segment, we don't yet have enough growth catalysts to overcome the pressures facing our life science and analytical instrumentation markets. Our HST industrial markets are performing as described earlier for FMT, with stable day rates and preferred -- deferred project activity. Despite some encouraging discussions from our semiconductor customers asking us to get ready to launch to support the next cycle of growth, we just haven't seen yet turn into accelerating releases or increased order positions.

We think we're close here as most major players are pointing to likely strong growth in 2025. Life sciences and analytical instrumentation performed in line with expectations, with a strong focus on innovations to support the next cycle of growth and excellent productivity to support margins as we await market recovery. As we said at the beginning of the year, we believe we are unlikely to see positive inflection for these markets until 2025.

FSDP had a strong quarter. Our dispensing teams are performing exceptionally well within emerging markets. Their share gains within India are nicely offsetting much of the pressure from their North American markets, as large retailers step back following a strong 2-year replenishment cycle.

Our Fire business continues to grow as industry throughput improves. They're also growing share through higher adoption of mobile platform automation. Finally, BAND-IT was affected by softness in auto and industrial demand, but continues to deliver very strong above-average profitability.

Finally, we were thrilled last week to announce the acquisition of Mott. We'll talk a bit more about the company in a moment as we update our work within capital deployment.

Turning to Slide 4. Although market headwinds persist, we are leveraging our strong technical and innovation capabilities as well as our close customer partnerships to position our business for growth across technology-enabled markets and applications.

Our materials processing technology, MP350 Microlyser Processor, won the Biotech Innovation Award at INTERPHEX, the leading global pharmaceutical and biotechnology conference. The MP350 is designed for production scale cell disruption, which is used in the manufacturing of many biotech products, such as antigens for vaccines and viral vectors supporting gene therapy.

In the life sciences area, our new Melles Griot XPLAN CCG Lens Series imaging system, released in February, is providing customer access to superior quality optics with off-the-shelf lead time. This aligns with our strategy to deliver leading innovation and operational scale to support our customers from prototype to production, positioning us well for growth.

During the second quarter, our Intelligent Water Inspection team at EPAC launched Verisighht Ultra. This inspection technology tackles challenging infrastructures with remote access and an intuitive digital interface, capturing and converting data into powerful insights in the inspection of wastewater management systems. This is one of the many examples of how we're helping municipalities deliver clean water to their communities.

We also received customer approval at our Trebor business for the next generation of sustainable ultrapure water heater and pump applications used to support the semiconductor wafer fabrication process. The Quantum NXT heaters have saved semiconductor manufacturers over 0.5 billion liters of ultrapure water this year alone. We anticipate this will provide long-term growth as the semiconductor market reaccelerates.

And in our Fire & Safety group, our teams unveiled the WildCAT solution for brush trucks used to fight wildland fires. Through a touchscreen application in the cab, firefighters can take control of essential water path functions, while stationary or on the move, in a much safer environment. With wildfire season clearly upon us in North America, this is a critical solution that can really make a difference.

Now turning to our disciplined capital deployment initiative on Slide 5. We continued to lever our strong balance sheet to tune our portfolio for profitable growth through strategic acquisitions. Last week, we announced the acquisition of Mott Corporation, a leader in the design and manufacturing of centered porous material structures and flow control solutions with deep material science knowledge and process control capabilities.

Mott develops highly engineered configurable mission-critical solutions for scalable high-quality applications. Their business is complementary to our broader Applied Materials Science Technology businesses within HST, including Muon, [ STC ] and Optical Technologies. And perhaps most impressively, they deliver for customers with an outstanding culture that fits really well with ours. We believe the addition of Mott will deliver value for IDEX via strong organic growth, EBITDA margin expansion to above HST average and near-term EPS accretion.

In addition to Mott, we acquired a small company, Subterra, on July 25. Subterra's technologies help digitize underground infrastructure. It will become part of the Intelligent Water platform within our FMT segment, adding an important piece to our analytics solution across wastewater collection systems.

Finally, as we optimize our portfolio, we continually reconsider the long-term growth prospects for all of our businesses. Occasionally and typically with smaller companies that like a path to scale, we decide to sell to an owner that can better maximize potential. During the second quarter, we divested Alfa Valvole for $45.5 million in cash. They operated within our FMT segment.

With that, I'll turn it over to Abhi to discuss our financial results.

[Abhishek Khandelwal, executive]

Thanks, Eric. Turning to the consolidated financial results on Slide 6. Please note that all comparisons are against the prior year period, unless otherwise stated.

Orders of [ $772 ] million were up 1% on a reported basis and up 2% organically. We saw mid-single-digit organic growth in FSDP and HST, which were partially offset by a mid-single-digit decline in FMT, driven by projects being pushed to the right. Second quarter sales of $807 million was down 5% reported and 4% organically. We experienced an 11% decline in HST, while FMT and FSDP were essentially flat as compared to the prior year period.

Second quarter gross margin and adjusted gross margin were 45.4%, an expansion of 70 basis points, driven by strong price cost and favorable operational productivity, partially offset by unfavorable mix, higher employee-related costs and lower volume leverage.

Second quarter adjusted EBITDA margin was 27.8%, down 60 basis points. However, as compared to Q1, adjusted EBITDA was up 180 basis points. The strong sequential expansion highlights our team's continued focus on deploying 80/20 and to drive profitability as we manage through challenging market dynamics. I will discuss the drivers of second quarter adjusted EBITDA on the next slide in a moment.

On a GAAP basis, our Q2 effective tax rate was 21.2% versus 22.4% in the prior period. The decrease was primarily due to a discrete benefit from research and development incentive resolution related to prior years from an international taxing authority. Second quarter net income was $141 million, generating an EPS of $1.86.

Adjusted net income was $156 million with adjusted EPS of $2.06, down $0.12. Free cash flow for the quarter was $118 million, a decrease of 2%. We achieved a conversion rate of 75% of adjusted net income, a 310-basis-point improvement on a year-over-year basis. We have a strong balance sheet, and this quarter, we repaid $25 million of the $50 million previously outstanding debt under our term facility, and we paid $52.2 million in cash dividends. The dividend was our 119th consecutive quarterly dividend payout.

Moving on to Slide 7, which details the adjusted EBITDA drivers. For the second quarter, adjusted EBITDA decreased by $17 million. The 4% organic sales reduction unfavorably impacted adjusted EBITDA by $23 million, flowing through at our prior year adjusted gross margin rate. The negative volume flow-through was partially offset by strong price cost spread of 100 basis points in the quarter and operational productivity, resulting in a $13 million benefit over the prior year.

In the quarter, we saw unfavorable mix driven by dispensing and lower overall industrial activity. These factors resulted in a negative 48.7% organic flow through. The impact of FX lowered adjusted EBITDA by $1 million, while acquisitions net of divestitures was flat on a quarter-over-quarter basis, as the benefits from our acquisitions were offset by adjusted EBITDA from divested companies. This resulted in a negative 42.4% flow-through for the second quarter.

I will now review segment level performance. Turning to Slide 8 and FMT segment. In Q2, orders decreased 4% organically, driven primarily by the cyclical decline in the ag market and push out in industrial project activity, as Eric discussed in his opening remarks. Organic sales were flat as lower volumes, particularly in our industrial safety and pump businesses were offset by continued strong price capture.

More specifically, we are seeing stable day rates across industrials. We're seeing project spending pushouts in the current macroeconomic climate. Our water businesses continue to benefit from strong municipal activity. While the ag markets are experiencing a cyclical downturn, our teams continue to make their own luck, and we are pleased with our team's performance against the current backdrop.

Adjusted EBITDA margin decreased 140 basis points due to higher discretionary spending, lower volume leverage and higher employee-related costs, partially offset by strong price cost spread and favorable operational productivity.

Moving on to Slide 9 and our HST segment. Despite slower-than-expected recovery in the semiconductor industry and delayed industrial projects due to demand softness, organic orders were up 5% year-over-year. Organic sales were down 11%, primarily driven by our Life Sciences & Analytical instrumentation markets. While the market is experiencing a transitional period, we continue to work closely with our customers on innovation as we position ourselves for growth, while we wait for the markets to recover.

While we are seeing early signs of encouragement in our semicon end markets, we have not yet seen the inflection in our orders. In line with our FMT industrial businesses, our HST industrial businesses are also experiencing project pushouts.

Q2 adjusted EBITDA margin for HST improved 10 basis points year-over-year, primarily due to the net accretive impact of acquisitions and divestitures. On an organic basis, adjusted EBITDA margin decreased 20 basis points, driven by lower volume leverage, unfavorable mix and higher employee-related costs, partially offset by operational productivity, strong price cost and lower discretionary spending. Sequentially, margins improved 150 basis points despite a sequential sales decline, which is a reflection of our strong focus on driving operational efficiency.

Now turning to Slide 10. Organic orders in our Fire & Safety/Diversified Products segment were up 6%. Organic net sales were up 1% compared to the prior year, driven by price capture across all markets and continued dispensing project wins in emerging markets. We are seeing positive trends within the Fire & Safety business as the OEMs continue to work their backlogs down. BAND-IT saw weakness tied to auto and weaker industrial project activity.

Q2 adjusted EBITDA margin declined 40 basis points year-over-year, primarily due to higher employee-related costs and lower volume leverage, partially offset by strong price cost and operational productivity.

With that, I would like to provide an update on our outlook for the third quarter and full year on Slide 11. Note that our guidance does not contemplate the impact from future acquisitions.

For the third quarter, we project organic sales to increase 0 to 1% compared to prior year. We anticipate an adjusted EBITDA margin of approximately 27%, with GAAP EPS in the range of $1.61 to $1.66, and adjusted EPS in the range of $1.85 to $1.90. On a year-over-year basis, we expect low single-digit organic sales decline in HST and FSDP and low single-digit growth in FMT.

Given our current view on the timing of end market recoveries, we are revising our full year outlook. We now expect revenue to decline 1% to 2% compared to our prior outlook of growth of 0 to 2%. Given the revised organic assumptions, we expect full year adjusted EBITDA margin of approximately 27% versus a prior outlook of approximately 28%.

We project GAAP diluted EPS to range from $6.85 to $6.95 compared to our previous guidance of $7.13 to $7.43, and adjusted EPS to range from $7.80 to $7.90 versus our previous outlook of $8.15 to $8.45.

The update to a full year revenue guidance implies mid-single-digit organic sales decline in HST with low single-digit growth in FMT and FSDP. We will continue to closely monitor the end markets, while maintaining our focused effort on driving profitable growth.

With that, I will turn it over to Eric for closing remarks.

[Eric Ashleman, executive]

Thanks, Abhi. I'm on Slide 12.

Today, along the way, we touched on each of our key value drivers: organic growth, inorganic growth and margin expansion. We continue to apply our IDEX operating model, an 80/20 philosophy across all aspects of our business. It frames our culture and drives our growth and profitability.

We are innovating and winning today with our best 80s customers in very attractive markets. We believe broader economic support will really amplify these efforts over time. We have stepped up inorganic efforts with a series of thematic proprietary acquisitions intended to drive above-average growth in advantaged markets. And we continue to strip complexity out of our businesses to support maximum financial leverage and impact.

Thanks again to our IDEX employees and partners around the world for all that you do to drive trusted solutions that improve lives.

With that, I'll turn it over to the operator for your questions.

[Operator]

[Operator Instructions] Our first question is coming from Mike Halloran from Baird.

[Michael Halloran, analyst]

So let's start by understanding the change in the guide here. If I hear the comments right, Eric, the underlying daily rates were relatively stable in the quarter. And demand commentary has, I don't know, maybe a touch of optimism to it, but there's been more project pushouts and timing-related things.

So the core of the question is, what's really changed from an end market dynamic as we move through the second quarter into the back half? The magnitude of the drop of the organic trends in the back half versus where it was previously seems more severe than the comments you're making. So I just kind of want to bridge the gap between the 2, if you would.

[Eric Ashleman, executive]

Yes. So look, I think you hit the first part of it dead on here. I kind of walked and I went back a little further, kind of walked it from December, all the way up to the present. And we've seen kind of this level of core rate stabilization since that initial pullback from the exuberance of Q1, right around that March time and it held through the quarter. And that's across the board in FMT and the industrial like portions of HST.

I think the 2 components that are most different from us relative to the last guidance, is we had anticipated some semicon launch in HST. There's a lot of signals set our way around ramps up in capacity. I mean, obviously, that sector had trouble with it last time. It just didn't materialize into orders. And in fact, we had some deferments in that area pretty late in the late innings of the second quarter, pushed into the back half that we've now got to keep an eye on.

The second piece, we never talk about project business as a massive part of IDEX. But I got to say that what changed here sort of mid-May on, and we saw a lot of it in June, some of it continuing into July. I think it's pinging off the 2 uncertainty elements that I talked about here. It's this notion of inflation and rate relief and when it's going to come, which has been sort of out there since that March time frame. Just a lot of political uncertainty as kind of the second thing.

So we've had these conversations with distributors, OEMs. We've asked them about their own businesses, how you're thinking about it, and you kind of consistently hear those 2 things. And then for us, it's manifested, as I said in the opening comments, not a cancellation or pullback in resourcing, but just approval loops that take longer to come together.

So for us, that played out. We saw it in FMT in a few sectors. We saw it across some of the markets in HST. And we saw it in that, frankly, the growth initiative file that we also referenced here that we were counting on to lift a bit for us in the back half. And in fact, some of those projects, too, have that same narrative and overhang.

So I think the optimism, through all of that, is that ultimately, those questions are going to be resolved. As they resolve, the fact that these are still resourced, we're still engaged, we're still talking about what comes next. I think that's where the comment -- the confidence comes from and the fact that it's sitting on a core foundation those day rates, what that tells you is that the system is still operating. It's still effective. People are maintaining things. Those 2 pieces together give you the long-term view that I think eventually, this sorts itself out.

[Michael Halloran, analyst]

So the follow then up on that then is, how do you think this recovery curve plays out? And if you listen to your comments on a lot of the price activity still there, more push out, more timing-oriented and some stability on the daily rates.

Is this a scenario when these things start hitting, we could see a pretty rapid recovery pace? I'm not saying this year, not even asking for a timing component to it. Or are you thinking something a little bit more iterative and modest as we think about moving into '25?

Because at the end of the day, it seems like you're saying, there's a lot of things underneath the service -- surface to be really positive about. And it's just a question of when they hit. And so just trying to understand the recovery timing from your perspective.

[Eric Ashleman, executive]

Yes. I'll kind of go through that in 2 dimensions, and I'm sure the second dimension, we'll talk about as well in terms of those kind of core sectors in HST that have been pressured for a while. But if I start where I just left off on the last discussion, the uncertainty attributable to those 2 dynamics kind of interest rate and where that's going to go, interest rate travel and geopolitical situations, good shot those are resolved to some degree here as we close out the year.

And we've seen in other occasions when things like that have been resolved, and there's a lot of captive energy, things have started pretty aggressively. We'll have to see. We'll have to see. I mean rates have been high for a while now. Does it take a while to fire that engine back up again in terms of investment?

Q4 and what we see in kind of the book-to-bill ratio there, I think given just the nature of where the election is and where some of these other decisions are going to play out will be a key input for us to understand kind of rate of travel into '25.

But I would say that the things that are embedded in those projects, the solutions that people are addressing with our technology, things that are being elongated now, I mean, frankly, they're overdue. They need to happen. We've kind of talked about this for a while. And I think I'm pretty optimistic that those ultimately get deployed and get deployed in a way that's favorable for us as we go forward.

I think the other side of it, that's where we're going to come back and take an eye at the Life Sciences & Analytical Instrumentation sector, which, as you know, has been kind of flat for us for a while now after an initial slide of recalibration in the first half of last year.

I think there's a little optimism there as well in the conversations we're having that we're closer to the end of that cycle than the middle or the beginning. We're coming up -- by the end of the year, it will be about 2 years that we've been experiencing that as our customers. We start to now look at the life cycle of the technology that's out there and the opportunity for refresh.

We're seeing indications of things like accelerating drug discovery and trials. There's a lot of innovation announcements that our customers are talking about, and we've got great content on the gear that lines up well with us.

I think on the China piece of that, I think our expectations have been calibrated for a while. We'll see. I think everyone's looking for signs of stimulus becomes effective there. But I see that's a little bit more optimistic in tone and tenor as well.

And then finally, on the semicon part, as I said in the remarks in the beginning, a lot of people referencing, hey, '25 looks like it's going to be a pretty strong cycle. And so we'll be looking for when does the bridge -- when does this bridge link us from here to there.

[Operator]

Our next question today is coming from Vlad Bystricky from Citigroup.

[Vladimir Bystricky, analyst]

So maybe just a quick question on free cash flow. I know I think you did about 75% conversion in the quarter. You talked about 100% plus for the year. So can you just talk about what needs to happen to hit that higher conversion rate for the year and sort of your level of visibility or confidence in that?

[Abhishek Khandelwal, executive]

Yes, Vlad, I can -- this is Abhi. I can take that. So first of all, when we think about the 75% for Q2 and compare it to prior years, it's in line with what we typically see in Q2, just the way the timing of the cash flows play out. I'll answer the other question, which is the confidence level in a cash flow north of 100%. We feel highly confident. That's our forecast for the year.

Things that we are focused on that we continue to drive is inventory reduction in line with where the top line is. As you think about the back half of the year and where our top line is, our teams are focused on driving inventory to the right levels that will drive working capital, and we feel pretty comfortable with us hitting our free cash flow target.

[Vladimir Bystricky, analyst]

Great. That's helpful, Abhi. Appreciate it. And then I wanted to dig in a little on FSDP. The plus 6% organic orders in the quarter, and it's pretty encouraging. I guess was there any bigger onetime orders in there to think about? Or sort of, again, your level of visibility to orders remaining positive in the back half if the macro holds as it is?

[Abhishek Khandelwal, executive]

Yes, I can give you color on that. So if you think about the order profile for Q2 and where we landed, that growth typically -- pretty much came from FSDP. And if I look at the segment and look at -- or look at the business and where they were, it was primarily driven by Fire or North America OEM demand. So that's where we saw the growth in Q2 from an order standpoint in FSDP.

Now keep in mind, in FSDP we also have dispensing. And so orders sometimes can get choppy because you might -- we've been talking a lot about the dispensing emerging market growth, and those come in bigger chunks of orders. So you could see something in Q1 that we ship throughout the year. But if you think about Q2 and the growth in Q2, it's tied to North America OEM demand that we saw in the quarter.

[Operator]

Our next question is coming from Nathan Jones from Stifel.

[Nathan Jones, analyst]

I think it's been a while since we've talked about fire OEM demand being positive. So that's good to hear. I wanted to follow up on the HST numbers. The guidance does imply that you're going to see a little bit of revenue improvement in the back half relative to the first half. Is that just the absence of inventory destocking that you saw through second half of '23 and into '24? And just how you think that's going to progress as we get into the back half?

[Eric Ashleman, executive]

Yes. Well, some of the cases where we talked about, the larger chunks that have been deferred and deferred here more recently, I mean those are lining up closer to the back half of the year. We, again, know what those programs are. We know what the platforms are. And ultimately, they do support the bridge to some of the growth that OEMs are talking about, specifically in the semicon area.

We have a couple of other HST programs that we've been monitoring for a while. I mean they're very, very milestone-based, and I'm pretty confident that those are going to hit as well. So I think it's largely attributable to those 2 things.

[Nathan Jones, analyst]

I guess, continuing to follow up on the project pushout kind of question here. Historically, when industrial companies have started to talk about projects being pushed out, but not canceled, that can be a precursor to projects getting pushed out for an extended period of time.

It doesn't sound like you're that concerned that we're in that kind of environment today where you can just say things that got pushed from the second quarter into the second half, get pushed into '25, et cetera, et cetera. Just comment on your confidence that we're not in that kind of environment where by the time we get to the fourth quarter, we're going to be talking about industrial orders that you thought were going to hit in the second half of '24 and now being pushed to '25?

[Eric Ashleman, executive]

So I certainly get the spirit of the question. I'd come back to the magnitude of the reference points here and what they are. So one of the benefits we have in those early indicator businesses that we always talk about in FMT is they're a great gauge of sensitivity to different narratives.

And even in the last call, one of the reasons I remarked about the dynamic that we've seen in the pullback in core rates in March and its alignment. So frankly, the hotter inflation read and the uncertainty of where rate relief was going to come in, it is just, in my mind, showed us the sensitivity level around that particular dynamic in that part of the narrative.

And that's maintained throughout. The second one being, frankly, the election cycle here in the U.S. Almost everything we're talking about is North American based and North America-centric, even in terms of the numbers, the way it's playing out.

So if you look at those 2 issues, which are ubiquitously showing up in the conversation of why things are being delayed or elongated or pushed to the right. We actually know that those 2 are going to have resolution points, but the certainty is pretty high, at least on the first and on the second, of course, we know it comes in November.

And we -- I've seen these cycles a couple of times before where that -- it's not unusual for things to be somewhat captive when these dynamics are playing out. I think the -- obviously, the post-inflation wave, that's a new one. But I think we're closer to resolution on it than the beginning and just that sensitivity and the way that these are lining up, I think it gives me some confidence that as we watch those go, you're going to see some things be relieved here.

[Operator]

The next question today is coming from Deane Dray from RBC Capital Markets.

[Deane Dray, analyst]

I [ don't know ] if you all were listening to one of your industrial peer conference call. I'm just kidding, but they were saying the exact same things about extended approval loops and some nervousness about election and some project pushouts. So the commentary is familiar and so you guys are not an outlier. So I just wanted to share that.

The question first is it's kind of like what we're not hearing about analytical instruments, life science destocking, you said it's in line with expectations. Is the destocking over? I know you got to be really careful about declaring that, but just what's your sense today.

[Eric Ashleman, executive]

Well, look, once -- I mean the way I look at a lot of these issues is you just kind of listening for Qs in conversations. And that's one of the reasons, as I talked about it earlier, I mentioned positive aspects like innovation, like drug trials, accelerating, like duration of the cycle and need for refreshes.

Honestly, at the customer level, that's the kind of things we're hearing about. It's not to suggest there aren't pockets of finished good inventory out there on a global basis. Again, it's super hard for us to see that. But what you don't hear is kind of a domination of the headlines with that aspect that we did earlier in the cycle.

So I still think it's uncertain in our own numbers and guide here. I mean we haven't called victory on it, and we've kind of held the line here for the rest of the year. But I am noticing that there is more positive commentary generally. And to be candid, I think we're just about ready to lap the duration of the run up here as well.

So I think it's a lot of those things converging. I'm probably most excited of any element in it, just the level of innovation that I know we've been participating in and I've been talking about, I think you're starting to see that now start to hit the market in a bigger way for our end customers. That in itself is a vote of confidence, if not in the exact short term, certainly in the medium and the long term.

[Abhishek Khandelwal, executive]

And Deane, this is Abhi. Just to build on what I just said, if I look at the performance this year and just look at the first half, quarter-over-quarter, 1 to 2, the performance has been relatively flat. So to Eric's point, we weren't expecting a recovery in Life Sciences this year. But if I look at the performance, it has been flat.

[Deane Dray, analyst]

Yes. That's exactly the way it appears to us, but just want to see if there was anything else below the radar screen. And then second question is given the kind of uncertain backdrop, how about you all making any changes in your discretionary spending? Any pullback in growth investments? You reaffirm your CapEx for the year, but any changes there that you would highlight or not changes that you would highlight?

[Eric Ashleman, executive]

Yes. I would say steady as she goes there. I mean, as we said before, growth investments, typically for us are people based. They're domain experts. They're the people that are really, really good engineering things and figuring things out with close proximity to customers.

The innovation cycle takes longer than a lot of people will recognize in mission-critical spaces like this. So making sure that people are engaged and doing the right work. That's always part of what we do. And maybe even more important now than in a relatively choppy period, you're staying on that case because you ultimately could feel that gap later on in our own growth numbers.

I will say, I referenced maybe more specifically, the work we're going to do with 80/20 as we talk about Mott coming on the board. And one of the things that that's going to help them do and it helps us across IDEX is that's actually a source of resource deployment and reallocation of resources that we have here from areas that are not as impactful to areas that are more impactful.

So as we play that out business to business and play it out in acquisitions, it's a way to kind of augment the power of resources in areas where we want to apply them without actually upping the spend profile overall. And we indicated that when we referenced it in the transaction as an area of margin lift for the company as they grow, but it's just representative of how we deploy it more generally and more broadly at IDEX.

[Abhishek Khandelwal, executive]

And Deane, this is will be -- I know you're going to see it in the commentary in the press release and even in the 10-Q, but if you look at FSDP and HST, discretionary spend is down. And where you will see an increase is FMT. But quite frankly, that's tied to our digitization effort. That's front end, and that's one of the growth best that we are focused on.

So overall, I'd say you'd see a discretionary reduction across the 2 businesses, with the exception of -- our 2 segments with the exception of FMT.

[Operator]

[Operator Instructions] Our next question today is coming from Matt Summerville from D.A. Davidson.

[Matt Summerville, analyst]

Just a couple of quick ones. First, can you quantify the level of price capture you saw in Q2? And remind us, is that consistent with what you saw in Q1? And then similarly, if you can also compare your organic book-to-bill in Q2 versus Q1? And then I have a follow-up.

[Abhishek Khandelwal, executive]

Yes, Matt, absolutely. So if I think about the price capture, it's in line with the guidance that we laid out for the year. So price capture for the quarter was closer to 2%. But the bigger thing that we talked about that we were focused on is the price/cost spread. And our price/cost spread for the quarter was 100 bps. And if you recall, what we have said, going into the year, we were targeting between 80 to 100 bps. So we're on the high end of the price/cost capture for the quarter.

From a book-to-bill standpoint for the quarter, we landed at 0.96 versus 1Q of 1.02. Now that said, part of this is the timing of when the blankets booked in the quarter. In Q1, we had a few blankets that got booked that we shipped throughout the year. Q2 had lesser of those. So the best way to think about our book-to-bill is as we go towards the tail end of the year, like Eric alluded to, one of the things that we are focused on is our book-to-bill ratio because that's where we see a lot of blankets come through that feed the revenue for 2025.

[Matt Summerville, analyst]

Got it. And then just a follow-up on the analytical instrumentation life sciences. I just want to be clear. At this point, is it -- are you thinking the inventory drawdown is indeed completely in the rearview mirror? And to that extent, are you seeing OEMs generally carry less inventory than they were pre-COVID? Or is the absolute stocking level reverting back towards something more in line with the pre-COVID level?

[Eric Ashleman, executive]

Yes. Well, so again, there's kind of 2 pockets of inventory. One, we have a lot more visibility to than another. So the inventory, let's say, between us and customers. So those would be components and things that we supply them. I mean the planning levels that they have today are pretty typical for what they've been in the past in terms of replenishment rates and how far away we are and how much lead time we're being asked to deliver.

So that's been, honestly, back in sync now for a while. The inventory of finished goods, which, of course, passed our customers and extend globally, less clear for us. But to the extent we have not seen further erosion in demand here, and we've been holding relatively flat and continue to project it that way.

I don't think it's -- we don't see it as a significant driver going forward and in fact, are leaning on those points of optimism looking for the turn, which we hope to be somewhere into 2025.

[Operator]

Our next question is coming from Joe Giordano from Cowen.

[Joseph Giordano, analyst]

So just inherent in the revenue guide for the second half of the year, what are you thinking for orders for FMT and HST like in dollars versus the 2Q level? Do they get better or worse from here?

[Abhishek Khandelwal, executive]

If I look at our guide and you kind of think about the back half that we have guided, yes, the orders do get better in terms of dollars sequentially from first half to second half.

[Joseph Giordano, analyst]

Okay. And then if I look -- and I think this is -- it's tough to analyze with companies now in the post-COVID, given how supply chain gets crazy. But if I look at all of your -- each of your segments independently on like a trailing couple of years, like if I look at all these since COVID, orders -- the excess orders over revenue, it's pretty significant still.

So like I would think that there's more backlog coverage than like the guidance suggests, given like from a trailing 3-year or whatever, there's significantly more orders than revenue. So like are you seeing customers not taking delivery as you think for orders that are in backlog? Or are you seeing cancellations there?

[Eric Ashleman, executive]

I want to make sure we're seeing it the same way. We -- I mean, typically, backlog, we're a smaller backlog company. We -- normal course of business for us is kind of half a quarter is assured, and we go find the rest. That's a general statement for IDEX that absolutely in the pandemic year has changed, like it did for everybody else.

I mean I think we doubled it kind of at the height here and had a quarter's worth of insurance, maybe a little bit more as people overordered and did everything they could for supply chain assurance, maybe sooner than many companies, we actually reverted back to a very typical backlog profile, and we've been there for a while now.

So kind of half a quarter in front of us, got to go hunt for the rest. So the dynamics in backlog for us are not that different. The lead times and replenishment that we're being asked to provide in all 3 segments is pretty typical. I think the only thing that's atypical here for us has been the level of project commitments and those discussions around when the next thing might be coming. And I'll just point back to the indicators that we talked about as to what's driving it.

[Operator]

And our next question is coming from Andrew Buscaglia from BNP Paribas.

[Andrew Buscaglia, analyst]

I wanted to focus on [Technical Difficulty] margins. I think you said in the past, exiting the year, you could see a little bit of a lift. It seems like guidance might imply that too. But in terms of getting back to that 30% -- that level, how much of it is more dependent on volume coming back versus mix?

Because I'm trying to gauge some of these higher growth areas coming back. I guess what are the dynamics as that pans out [indiscernible] margins?

[Abhishek Khandelwal, executive]

Andrew, I think you cut off for a second or 2 there, so I might have missed the piece. But let me try to answer that question. If I don't completely get to your answer, then just ask me again, and I'll do it.

But if you just take a step back and kind of think about where we are your general comment about depending on volume, volume is a big part of it because, of course, when we see top line growth, we lever really nicely on our businesses. So that is a big component of how margin expansion happens. But that said, though, given where we are you will notice, sequentially, our margin profile got better by 180 basis points, right, despite very minimal help from volume.

And that's really tied to the work that we do around 80/20 complexity reduction and cost out in the light of where we've been. So as you think about the balance of the year and how we're thinking about the year, exiting Q4, so I want to be very careful. I'm talking about rates exiting Q4, not full year rates. We're thinking about HST closer to that 28% kind of profile on EBITDA, FMT closer to 34%, and then FSDP in the 28% to 29% range from an EBITDA standpoint.

[Andrew Buscaglia, analyst]

Very helpful. And yes, I wanted to focus on Fluid & Metering. The municipal water strength has been a nice story for a while for you and others. Where are you guys do you think in that inning -- or what inning do you think you guys are in? And how much of your business is influenced by government spending or government funding?

[Eric Ashleman, executive]

Well, so look, I think the cycle plays out for a while, mainly because the intentionality of that funding that's kind of spread over much of the industry. It just takes a long time to spend. These are complex engineering projects for multiple players, not just us.

A good portion of things that have been announced is not actually spent yet or engineered. So I always thought of this as kind of a multiyear safety blanket or a warm comfortable blanket, either one. We're positioned actually in -- we do an important work to help spend that money. So I think it's one of the reasons we're seeing that the strength in our business. We do analytical work that actually helps write the capital request.

So essentially, many of our customers are actually engineers, civilian engineers that are then using that data to suggest projects that are going to tap into funding of the type that you're talking about here. So there's a portion of it that is intentional and it's coming from announced government programs.

A decent amount of municipality, of course, is government-funded, but that's ultimately through taxation. And we have -- look, we participate in the industrial water side of this, too, and that, of course, is in tie to private markets. But I think there's a nice run here overall, if for no other reason that it just takes a while to frankly, bring all this to fruition.

[Operator]

Your next question today is coming from Rob Wertheimer from Melius Research.

[Robert Wertheimer, analyst]

I apologize if this -- I got cut out for a while in the audio. So if I missed something or belabor a point that you've covered, you can just cut me off. But on the project delay side, is that tied to specific government policies that might open up one way or the other? Or is it just more of a general unease or uncertainty that has affected how people are willing to spend?

[Eric Ashleman, executive]

Yes. So we did touch on that before a bit, but I think it's worth a second go around. I mean it's very specific around 2 very general themes, one around sort of the cost of money and the fact that it's been higher for longer, and there's uncertainty as to the rate of travel to something better. That's all about inflation and interest rate and that dynamic, which everybody is watching.

And I think the second one is around political uncertainty and uncertainty of outcomes given the polarization here in North America for approaches. In our conversations, it doesn't really then travel below that to something more specific because frankly, our business is -- it's more diverse. It's spread across different places where at the component level. So we're not as heavily indexed to a program or another program.

It's kind of like the answer I gave on the water side of it. The fact that there's intentionality there and it's going to take multiple years to spend it is kind of good enough for us to then participate in the way we do in municipalities and industries across the globe to participate in that. So it's very generalized as we're thinking of it here.

[Robert Wertheimer, analyst]

Perfect. And then could you remind us the rate-sensitive businesses within FMT that you're kind of using as guidelines. What's the nature of the activity there in the business? Could you just give us a little bit more background around that, and I will stop there.

[Eric Ashleman, executive]

Yes. It's a series of businesses in the FMT, where a lot of them are kind of pumps and bulbs and fluids. So they're used for a broad array of purposes. They go to market in -- typically and through industrial distribution. And because of the kind of customized nature of the way that we do things in our rapid fulfillment, we can get an order on a Monday, ship it on a Wednesday and it's in service on a Friday.

I say all that because what they -- because of the nature of that, they provide really good insight into kind of action consumptive activities across the board. And it's -- frankly, it's more than 50% of the order flow in those businesses. So we use them as diagnostics to tell us kind of what's the state of health there.

And as we've talked about them here, what we've said is there's 2 dimensions that we see at work. The core day-to-day rates, which is this short-term fulfillment, think of it as somebody maintaining their factory as they run in 2 shifts, that's steady. It has been steady, and it's really back to the assumptions we had in the fall. It was only interrupted briefly to the positive for a 3-month period as I think there was more anticipation that we're going to have more favorable rate relief. And it sort of came back down and it's been steady state.

There's a tie-in there with project work and project work in our world, I don't think of them as stadiums or massive things like that. It could be a simple back-end expansion onto a food plant or something like that. It kind of moves you from a pump or 2 to something like 40 or 50 for us. But that's tied to an approval process and a discrete decision that's important. And that's kind of the piece we've said has been hung up in the works here with those 2 more generalized themes that I talked about.

So that's what the insight is telling us. We're very happy to see that the day rates are supportive of just strong and relatively stable industrial activity. And we look forward to the day the uncertainty leaves the project-driven side of it, which is going to complement it overall.

[Operator]

We reached the end of our question-and-answer session. I'd like to turn the floor back over to management for any further or closing comments.

[Eric Ashleman, executive]

Well, thank you. Listen, I recognized we struggle a bit here to find our organic guidance footing over the last 6 quarters. I realized a lot of that chop is coming out of the HST segment. And I'm fully aware that we're disproportionately investing in HST organically and inorganically is a key element of our strategy.

What I want to make sure you understand is this is the right call for our business. Even in a period of uncertain transition for some of these foundational markets, we've talked about a lot here today. 1/3 of this segment lays across 2 verticals within Life Science & Analytical Instrumentation and advanced semicon manufacturing. They're pressured today, but no doubt they're going to have wins at their backs for years to come.

We just built another 1/3 of the segment that allows us to lever the supplied material science technology to a really narrow band of high-quality application areas, and the Mott acquisition completes this phase of the build. And then the remaining third, it's composed of high-quality businesses, where it's all #1 in their respective niches and very, very IDEX-like in the way they function.

So together, we're innovating to set really critical specification points that are going to position us for leadership in the years to come, markets that are going to shape our futures. And we'll see the financial benefit of that play out just as we've seen it play out in the legacy businesses of FMT and FSDP. It's really important that we kind of get IDEX into the mix as these markets form up and launch.

So I look forward to walking you through our progress on that in the quarters and the years to come, and I wish you all a good day. Thanks so much.

[Operator]

Thank you. That does conclude today's teleconference. You may disconnect your lines at this time, and have a wonderful day. We thank you for your participation today.